Abstract Number: 2140 • ACR Convergence 2022
Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
Background/Purpose: Psoriatic arthritis (PsA) is a chronic systemic inflammatory musculoskeletal disease. The potential relationship between PsA therapies and specific safety events such as major adverse…Abstract Number: 2144 • ACR Convergence 2022
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…Abstract Number: 2145 • ACR Convergence 2022
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
Background/Purpose: PsA is a chronic, systemic inflammatory disease with a variety of clinical manifestations including arthritis, enthesitis, and dactylitis and is associated with skin and…Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…Abstract Number: 2034 • ACR Convergence 2022
What Is the Best Initial Screening for Suspected Sjögren’s Disease?
Background/Purpose: During the COVID-19 pandemic the routine diagnostic procedure in Sjögren's disease (SS) was highly hampered. The aim of our study was to determine in…Abstract Number: 2086 • ACR Convergence 2022
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…Abstract Number: 1546 • ACR Convergence 2022
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…Abstract Number: 2118 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…Abstract Number: 2142 • ACR Convergence 2022
Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…Abstract Number: 2127 • ACR Convergence 2022
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Background/Purpose: Recent guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend that psoriatic arthritis (PsA) therapy achieve lowest possible…Abstract Number: 2095 • ACR Convergence 2022
Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry
Background/Purpose: There is currently no agreement on which scale should be used to evaluate SLE disease activity. The aim of this study was to analyze…Abstract Number: 2037 • ACR Convergence 2022
Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands and extra glandular manifestations…Abstract Number: 2039 • ACR Convergence 2022
The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren's syndrome (pSS) often results in dysfunction of the salivary glands (hyposalivation and xerostomia) and substantial decrease in patient quality of life. High…
- « Previous Page
- 1
- …
- 425
- 426
- 427
- 428
- 429
- …
- 2425
- Next Page »